Head-to-head · WeighScore
Edessa vs June Health
By GLP-1 ScorecardUpdated
Score comparison
Edessa has the higher recorded score — 70.8/100 to 63/100.
Edessa grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Clean three-rung tables one click in, behind a homepage whose three cards all quote six-month rungs and whose cheapest belongs to a different drug.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Edessa | June Health |
|---|---|---|
| WeighScore | 70.8/100 | 63/100 |
| Grade | C | C |
| Site position | #112 | #295 |
| Semaglutide | $179/mo month-to-month injectable ($135 only on a 6-month prepay) | $179/mo (starting dose, compounded) |
| Tirzepatide | $239/mo month-to-month ($209 only on a 6-month prepay) | $179/mo (starting dose, compounded) |
| Coverage | Not publicly listed | Coverage not published |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Yes | Yes |
Site position #112 · C
Strengths
- Each product page carries a plain three-rung table, so the commitment behind every figure is visible
- "Same price, every dose" is printed on each product page
- Names its operating entity and a full street address in Las Vegas, Nevada
- All-inclusive: provider consultation, medication, free expedited shipping, ongoing check-ins and 24/7 clinical support, and HSA and FSA eligible
- An oral tablet sits beside the two injections
What to consider
- The homepage leads with "Start for just $135", a six-month prepay on the semaglutide injection; month-to-month tirzepatide is $239
- All three homepage cards quote the six-month rung, so the real monthly rates appear only after a click
- Its Terms give two corporate forms for the same company in one clause — "Edessa Group, LLC, a Nevada corporation"
- "Join 100,000+ successful GLP-1 patients" carries no source, and the money-back guarantee's terms are on no marketing page
- No lab or monitoring protocol is published
Site position #295 · C
Strengths
- Offers both injectable and oral compounded semaglutide and tirzepatide
- Semaglutide starts at $179/mo (injectable) or $187/mo (tablets) — tirzepatide from $179/mo (injectable)
- Full per-dose price list published on-site with no signup required to view it
- Provider consult ('licensed clinician evaluation') is bundled into the displayed price
- Free discreet shipping advertised with 2-3 day delivery
What to consider
- No accessible Terms of Service or Privacy Policy — footer links go nowhere and standard URL guesses 404
- No LegitScript seal or other pharmacy-verification badge found anywhere on the site
- Legal entity, prescribing medical group, and compounding pharmacy partner are not named
- Domain was registered in May 2026 — a brand-new storefront with no independent reviews found
- Also sells 'MR-3' (retatrutide), a GLP-1/GIP/glucagon agonist with no FDA approval for any use
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.